3 months ago
The merger will create a publicly traded company focused on advancing Caldera's lead inflammatory bowel disease therapy, with financing expected to fund operations into 2029.
Synlogic (USOTC:SYBX) agreed to merge with privately held Caldera Therapeutics in an all-stock transaction to create a new public company.
A concurrent upsized private placement is expected to raise approximately $278 million to support development of CLD-423 through Phase 2 clinical trials.
The combined company will operate as Caldera Therapeutics and intends to list on the Nasdaq Capital Market under the ticker symbol CALD.
CLD-423 is a potential first-in-class bispecific antibody targeting TL1A and IL-23p19 for ulcerative colitis, Crohn's disease, and other immune-mediated disorders.
#disease #sybx
Synlogic (USOTC:SYBX) agreed to merge with privately held Caldera Therapeutics in an all-stock transaction to create a new public company.
A concurrent upsized private placement is expected to raise approximately $278 million to support development of CLD-423 through Phase 2 clinical trials.
The combined company will operate as Caldera Therapeutics and intends to list on the Nasdaq Capital Market under the ticker symbol CALD.
CLD-423 is a potential first-in-class bispecific antibody targeting TL1A and IL-23p19 for ulcerative colitis, Crohn's disease, and other immune-mediated disorders.
#disease #sybx
